C
Christophe Van Steenkiste
Researcher at Ghent University Hospital
Publications - 50
Citations - 1272
Christophe Van Steenkiste is an academic researcher from Ghent University Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 33 publications receiving 1089 citations. Previous affiliations of Christophe Van Steenkiste include University of Antwerp.
Papers
More filters
Journal ArticleDOI
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.
Sara Van de Veire,Ingeborg Stalmans,Femke Heindryckx,Hajimu Oura,Annemilaï Tijeras-Raballand,Thomas Schmidt,Sonja Loges,Imke Albrecht,Bart Jonckx,Stefan Vinckier,Christophe Van Steenkiste,Sonia Tugues,Sonia Tugues,Charlotte Rolny,Maria De Mol,Daniela Dettori,Patricia Hainaud,Lieve Coenegrachts,Jean Olivier Contreres,Tine Van Bergen,Henar Cuervo,Wei Hong Xiao,Carole Le Henaff,Ian Buysschaert,Behzad Kharabi Masouleh,Anja Geerts,Tibor Schomber,Philippe Bonnin,Vincent Lambert,Jurgen Haustraete,Serena Zacchigna,Jean-Marie Rakic,Wladimiro Jiménez,Agnès Noël,Mauro Giacca,Isabelle Colle,Jean-Michel Foidart,Gérard Tobelem,Manuel Morales-Ruiz,José Vilar,Patrick H. Maxwell,Stanley A. Vinores,Stanley A. Vinores,Geert Carmeliet,Mieke Dewerchin,Lena Claesson-Welsh,Evelyne Dupuy,Hans Van Vlierberghe,Gerhard Christofori,Massimiliano Mazzone,Michael Detmar,Desire Collen,Peter Carmeliet +52 more
TL;DR: It is shown that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease and warrant further testing of anti-PlGF therapies.
Journal ArticleDOI
Alteration of protein glycosylation in liver diseases.
TL;DR: An overview of altered protein glycosylation in different etiologies of liver fibrosis / cirrhosis and hepatocellular carcinoma and some recently developed glycomic techniques that could potentially be used in the diagnosis of liver pathology are given.
Journal ArticleDOI
Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture
Sven Francque,Wim Laleman,Len Verbeke,Christophe Van Steenkiste,Christophe Casteleyn,Wilhelmus J. Kwanten,Christophe J. Van Dyck,Michiel D’Hondt,A. Ramon,Wim Vermeulen,Benedicte Y. De Winter,Eric Van Marck,Veerle Van Marck,Paul A. Pelckmans,Peter Michielsen +14 more
TL;DR: Severe steatosis induces a haemodynamically significant increase in intrahepatic resistance, which precedes inflammation and fibrogenesis, both functional (endothelial dysfunction and increased thromboxane and ET-1 synthesis) and structural factors are involved.
Journal ArticleDOI
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice.
Christophe Van Steenkiste,Jordi Ribera,Anja Geerts,Montse Pauta,Sonia Tugues,Sonia Tugues,Christophe Casteleyn,Louis Libbrecht,Kim Olievier,B. Schroyen,Hendrik Reynaert,Leo A. van Grunsven,Bram Blomme,Stephanie Coulon,Femke Heindryckx,Martine De Vos,Jean Marie Stassen,Stefan Vinckier,José Altamirano,Ramon Bataller,Peter Carmeliet,Hans Van Vlierberghe,Isabelle Colle,Manuel Morales-Ruiz +23 more
TL;DR: PlGF is a disease‐candidate gene in liver cirrhosis, and inhibition of PlGF offers a therapeutic alternative with an attractive safety profile, indicating a previously unrecognized profibrogenic role of Pl GF.
Journal ArticleDOI
Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment
Sarah Raevens,Anja Geerts,Christophe Van Steenkiste,Xavier Verhelst,Hans Van Vlierberghe,Isabelle Colle +5 more
TL;DR: An overview on the hepatopulmonary syndrome and portopul pulmonary hypertension with primary focus on diagnosis and recent knowledge regarding pathogenesis and therapeutic targets is provided.